PT  - JOURNAL ARTICLE
AU  - Gao, Ru-Shan
AU  - Rosenlof, Karen
TI  - Mortality rate and estimate of fraction of undiagnosed COVID-19 cases in the US in March and April 2020
AID  - 10.1101/2020.05.28.20116095
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.28.20116095
4099  - http://medrxiv.org/content/early/2020/05/30/2020.05.28.20116095.short
4100  - http://medrxiv.org/content/early/2020/05/30/2020.05.28.20116095.full
AB  - We use a simple model to derive a mortality probability distribution for a patient as a function of days since diagnosis (considering diagnoses made between 25 February and 29 March 2020). The peak of the mortality probability is the 13th day after diagnosis. The overall shape and peak location of this probability curve are similar to the onset-to-death probability distribution in a case study using Chinese data.The total mortality probability of a COVID-19 patient in the US diagnosed between 25 February and 29 March is about 21%. We speculate that this high value is caused by severe under-testing of the population to identify all COVID-19 patients. With this probability, and an assumption that the true probability is 2.4%, we estimate that 89% of all SARS-CoV-2 infection cases were not diagnosed during this period.When the same method is applied to data extended to 25 April, we found that the total mortality probability of a patient diagnosed in the US after 1 April is about 6.4%, significantly lower than for the earlier period. We attribute this drop to increasingly available tests. Given the assumption that the true mortality probability is 2.4%, we estimate that 63% of all SARS-CoV-2 infection cases were not diagnosed during this period (1 – 25 April).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a statistical analysis of public data, and does not fall under any clinical trial guidelines.Funding StatementNo funding was received to do this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human subjects were involved in this work, it is a statistical analysis of public COVID-19 data, hence there are no necessary IRB and/or ethics committee approvals needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed came from the website www.worldometers.info, and this is publicly available. https://www.worldometers.info/coronavirus/country/us/